US 12,234,460 B2
Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
Jonas Bovijn, Tarrytown, NY (US); Olukayode Sosina, Tarrytown, NY (US); Sirui Zhou, Montreal (CA); Luca Andrea Lotta, Tarrytown, NY (US); Aris Baras, Tarrytown, NY (US); and John Brent Richards, Montreal (CA)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US); and The Royal Institution for the Advancement of Learning/McGill University, Montreal (CA)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US); and The Royal Institution for the Advancement of Learning / McGill University, Montreal (CA)
Filed on Dec. 21, 2023, as Appl. No. 18/392,181.
Application 18/392,181 is a continuation of application No. 17/816,084, filed on Jul. 29, 2022, granted, now 11,891,607.
Claims priority of provisional application 63/230,707, filed on Aug. 7, 2021.
Prior Publication US 2024/0200079 A1, Jun. 20, 2024
Int. Cl. C12N 15/113 (2010.01); A61K 31/4535 (2006.01); A61K 31/565 (2006.01); A61K 31/57 (2006.01); A61K 31/663 (2006.01); A61K 31/675 (2006.01); A61K 38/23 (2006.01); A61K 38/29 (2006.01); C07K 16/28 (2006.01); C12Q 1/6883 (2018.01)
CPC C12N 15/1138 (2013.01) [A61K 31/4535 (2013.01); A61K 31/565 (2013.01); A61K 31/57 (2013.01); A61K 31/663 (2013.01); A61K 31/675 (2013.01); A61K 38/23 (2013.01); A61K 38/29 (2013.01); C07K 16/2875 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/156 (2013.01)] 25 Claims
 
1. A method of treating a subject having decreased bone mineral density, an osteopenia, Type I osteoporosis, Type II osteoporosis, or secondary osteoporosis or at risk of developing decreased bone mineral density, an osteopenia, Type I osteoporosis, Type II osteoporosis, or secondary osteoporosis the method comprising administering a Cluster of Differentiation 109 (CD109) inhibitor to the subject, wherein the CD109 inhibitor comprises:
a) LY294002; or
b) a Cas protein and guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within a CD109 genomic nucleic acid molecule.